Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,800 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 37,800 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $39.03 | $0.00 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · derivative · entry 5 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-06-05 F5 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-029068 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 944 | $46.51 | $43,905.44 |
DisclosureSEC source: 0001209191-19-029068 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $46.40 to $46.555. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,056 | $45.83 | $231,716.48 |
DisclosureSEC source: 0001209191-19-029068 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,644 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $45.19 to $46.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-19-029068 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-025183 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $48.09 | $192,360.00 |
DisclosureSEC source: 0001209191-19-025183 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $48.00 to $48.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-19-025183 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-024312 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 573 | $53.51 | $30,661.23 |
DisclosureSEC source: 0001209191-19-024312 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $53.41 to $53.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,427 | $52.95 | $181,459.65 |
DisclosureSEC source: 0001209191-19-024312 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,273 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $52.405 to $53.39. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-19-024312 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-063912 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,600 | $41.56 | $108,056.00 |
DisclosureSEC source: 0001209191-18-063912 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $41.49 to $41.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,400 | $40.88 | $57,232.00 |
DisclosureSEC source: 0001209191-18-063912 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,300 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $40.47 to $41.39. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-063912 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 23:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-059051 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 23:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 600 | $40.36 | $24,216.00 |
DisclosureSEC source: 0001209191-18-059051 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $40.26 to $40.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 23:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,400 | $39.67 | $134,878.00 |
DisclosureSEC source: 0001209191-18-059051 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,300 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $39.24 to $40.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 23:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-059051 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-055804 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,750 | $55.52 | $208,200.00 |
DisclosureSEC source: 0001209191-18-055804 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $55.06 to $55.81. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 250 | $53.88 | $13,470.00 |
DisclosureSEC source: 0001209191-18-055804 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,450 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $53.87 to $53.885. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-055804 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-051550 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,200 | $59.41 | $71,292.00 |
DisclosureSEC source: 0001209191-18-051550 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $59.00 to $59.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,800 | $58.63 | $164,164.00 |
DisclosureSEC source: 0001209191-18-051550 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $58.00 to $58.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-051550 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 21:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047481 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 21:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,450 | $60.65 | $148,592.50 |
DisclosureSEC source: 0001209191-18-047481 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $60.25 to $61.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 21:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,550 | $59.70 | $92,535.00 |
DisclosureSEC source: 0001209191-18-047481 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,150 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $59.25 to $60.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 21:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-047481 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-043513 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $64.35 | $257,400.00 |
DisclosureSEC source: 0001209191-18-043513 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $64.00 to $64.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 22:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-043513 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 22:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-038871 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 22:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $58.19 | $232,760.00 |
DisclosureSEC source: 0001209191-18-038871 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $57.925 to $58.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 22:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-038871 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $55.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036513 · doc4.xml · derivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036513 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-031377 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $51.83 | $207,320.00 |
DisclosureSEC source: 0001209191-18-031377 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $51.35 to $52.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-031377 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 22:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-025747 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 22:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $47.69 | $190,760.00 |
DisclosureSEC source: 0001209191-18-025747 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $47.30 to $48.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 22:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-025747 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-020340 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,100 | $53.05 | $58,355.00 |
DisclosureSEC source: 0001209191-18-020340 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F3 · price: The shares were sold at prices ranging from $52.75 to $53.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.